Live In Play®
Updated: 14-May-26 06:01 ET
AZN:  AstraZeneca reports Phase III VOLGA data for Imfinzi combinations in muscle-invasive bladder cancer  (187.72)
  • AstraZeneca said perioperative Imfinzi plus neoadjuvant enfortumab vedotin demonstrated statistically significant and clinically meaningful improvements in both event-free survival and overall survival in the Phase III VOLGA trial for muscle-invasive bladder cancer.
    • The study enrolled patients who were ineligible for or declined cisplatin-based chemotherapy.
    • A separate regimen combining perioperative Imfinzi plus Imjudo with neoadjuvant enfortumab vedotin also showed statistically significant improvement in event-free survival and a favorable overall survival trend, though OS was not statistically significant at the interim analysis.
    • Co said safety and tolerability were consistent with known profiles of the individual therapies, with no new safety signals identified.
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.
Send
Chat Icon